Breaking News

Tweet TWEET

Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association

Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the
    63rd Annual Meeting of the American Association for the Study of Liver
                               Diseases (AASLD)

PR Newswire

NEW HAVEN, Conn., Nov. 9, 2012

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --

Event: HCV Connection Media Briefing
Date:  Monday, November 12
Time:  7:45 a.m. Eastern Standard Time
Where: Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199;
       Also available by Webcast (link will be provided upon request)

The content of the media briefing will include the following themes and
information:

  oAn overview of HCV and the current epidemic worldwide
  oA compelling historical and scientific context for understanding the new
    era of HCV therapies and the emergence of patient-guided therapy
  oA brief review of first and second-generation direct-acting antiviral
    therapies, including important new developments in drug discovery
  oA detailed look at Achillion Pharmaceutical's portfolio aimed at curing
    HCV in a complex and diverse patient population

Following the briefing there will be a Question & Answer session with leading
experts in HCV including:

  oFred Poordad, MD, Chief Medical Officer of the Texas Liver Institute and
    Alamo Medical Research, San Antonio, Texas
  oAndrew Muir, MD, Director, Gastroenterology and Hepatology Research Group,
    Duke Clinical Research Institute, Durham, North Carolina
  oThe session will also be moderated by Lisa Stark of ABC News

Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated
to bringing important new treatments to patients with infectious disease. The
Company's highly skilled and experienced discovery and development teams have
identified and advanced multiple therapeutic compounds, many with novel
mechanisms or attributes. Achillion is focused on solutions for the most
challenging problems in infectious disease including hepatitis C (HCV) and
resistant bacterial infections. Please visit www.achillion.com for additional
information.

SOURCE Achillion Pharmaceuticals, Inc.

Website: http://www.achillion.com
Contact: Emily Johnson, Emily.johnson@ogilvy.com, +1-212-880-5316